Federal Biotechnology Workforce Assessment Act
The Federal Biotechnology Workforce Assessment Act directs the Director of the Office of Personnel Management, working with a defined set of federal agencies, to identify the federal biotechnology workforce and assess current and future staffing needs. The bill covers agencies such as Agriculture, Defense, Health and Human Services, Homeland Security, Energy, EPA, NASA, NSF, and others designated by OPM. It requires the assessment to estimate the number of biotechnology positions needed now and over the next 5 and 10 years, determine how many are currently filled, and describe the roles, qualifications, education, training, seniority, and security clearance requirements for those jobs.
The bill also requires analysis of workforce management issues affecting biotechnology positions, including whether current OPM job classifications accurately track these roles and whether new occupational series or codes should be created. It further asks for an accounting of security clearance needs and the appropriations required to obtain them, as well as identification of workforce development challenges and possible solutions. The report must also evaluate the use of current federal employees with additional training, interagency details, outside experts, and public-private talent exchanges to meet biotechnology staffing needs, with a report due to Congress within 180 days of enactment.
If enacted, the bill would not directly create new biotechnology jobs or change substantive program law, but it would require OPM and multiple federal agencies to conduct a government-wide workforce study and report to Congress. It would affect federal personnel management practices by examining occupational classifications, security clearance needs, training pathways, interagency assignments, and public-private talent exchange mechanisms for biotechnology-related work. The main affected parties would be OPM, the listed federal agencies, and federal employees or outside experts who may be used to fill biotechnology positions.
The available context suggests a generally positive, oversight-oriented posture toward the bill, with bipartisan sponsorship and no recorded committee debate or votes indicating opposition. The measure appears to be framed as a workforce planning and modernization effort rather than a controversial policy change. Because there are no transcripts or roll-call votes provided, there is little evidence of formal support or criticism beyond the bill’s introduction and referral.
The bill’s main points of potential contention are administrative and budgetary rather than ideological. It requires agencies to quantify security clearance needs and the additional appropriations needed to obtain them, which could raise concerns about cost, staffing capacity, and clearance bottlenecks. Another possible issue is whether OPM should create new occupational series or codes for biotechnology positions, and whether agencies should rely more heavily on retraining current employees, interagency details, outside experts, or public-private talent exchanges. No specific opposing arguments are recorded in the provided materials.